Submit manuscript...
International Journal of
eISSN: 2577-8269

Family & Community Medicine

Opinion Volume 6 Issue 2

The importance of D-DIMER values in COVID-19 patients with pulmonary thromboembolism in the two first years of the pandemia

André Luis Valera Gasparoto,1 Tania Leme da Rocha Martinez,2 Ana Paula Pantoja Margeotto,2 Adenilton Rampinelli,1 Anita L R Saldanha,2 Eduardo Neris,1 Thomaz Braga Ceglias,1 Raoni Rego Godinho,1 Otávio Castilho1

1 Intensive Care Unit, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil
2Nephrology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil

Correspondence: Tania Leme da Rocha Martinez, BP, Rua Comandante Ismael Guilherme, 358 - - Jardim Lusitânia, 04031-120 - São Paulo – SP, Brazil, Tel 55 11 98323-9863, Fax 55 11 3842-3789

Received: March 08, 2022 | Published: March 18, 2022

Citation: Gasparoto ALV, Martinez TLR, Margeotto APP, et al. The importance of D-DIMER values in COVID-19 patients with pulmonary thromboembolism in the two first years of the pandemia. Int J Fam Commun Med. 2022;6(2):56-57. DOI: 10.15406/ijfcm.2022.06.00264

Download PDF


The COVID-19 pandemic has posed a big challenge to the healthcare community and many stakeholders. According to clinical studies, D-Dimer assays may be the "first line" of technical screening in symptomatic outpatients with suspected venous thrombosis or pulmonary embolism. This same affirmation may be applied to COVID-19 as its cause. In this study the comparison of the first two years of the COVID-19 appears the tendency of treatment decision making based in D-Dimer levels being a less important parameter. Many patients with COVID-19 have been observed to present with prominently elevated D-Dimers, findings which have been postulated to reflect underlying thromboembolic burden, which have been associated with increased mortality among such patients.

Keywords: thromboembolism, COVID-19, intensive care unit, anticoagulation, pulmonary


ICU, intensive Care Unit; PTE, pulmonary thromboembolism



The aim of the study was to evaluate whether the prevalence of pulmonary thromboembolism (PTE) was higher in 2021 compared to 2020 of patients hospitalized by COVID-19 in an Intensive Care Unit (ICU).1–7


The methods were based on retrospective and comparative analysis among patients hospitalized by COVID-19 in an ICU since the beginning of the pandemic. All patients were receiving prophylactic or therapeutic anticoagulation. Patients with PTE were those confirmed by chest angiotomography or in those who did not have transport conditions to perform the ct angiography, but presented high probability for PTE based on echocardiographic criteria (significant increase in pulmonary artery systolic pressure and right ventricle dysfunction). All patients with presumed PTE had echocardiogram on ICU admission with parameters within the normal range. A total of 110 patients were evaluated in 2020 and 115 patients in 2021. The comparison of the two groups of patients between the years of 2020 and 2021 were comparable as to age groups, sexes and occurrence of all the mentioned risk factors.


The results observed that 8.8% (n=8) patients admitted in 2020 presented confirmed or presumed PTE. In 2021, 39% (n=45) had a presumed or confirmed diagnosis of PTE.


Some hypotheses for these results are: most patients in 2020 received full anticoagulation due to the elevated D-dimmer, even if there is no confirmation or echocardiographic changes. In 2021, after studies robustly demonstrated that full anticoagulation increased the risk of major bleeding, prophylactic anticoagulation (regardless of laboratory value of D-dimmer) became the choice. Only patients with presumed or confirmed diagnosis of thrombosis are receiving full anticoagulation.8–10


Can the new strains be more thrombogenic? Certainly they are variables that need to be further studied, despite the small number of patients evaluated.



Conflicts of interest

No conflict of interest.


  1. Zhan H, Chen H, Liu C, et al. Diagnostic value of D-Dimer in COVID-19: a meta-analysis and meta-regression. Clin Appl Thromb Hemost. 2021;27:10760296211010976.
  2. Tilliridou V, Kirkbride R, Dickinson R, et al. Pulmonary embolism severity before and during the COVID-19 pandemic. Br J Radiol. 2021;94(1123): 20210264.
  3. Mulder MMG, Brandts L, Brüggemann RAG, et al. Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort. Thromb J. 2021;19(1): 35.
  4. McGonagle D, Bridgewood C, Meaney JFM. A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe COVID-19. Lancet Respir Med. 2021;9(6): 665–672.
  5. Dhawan RT, Gopalan D, Howard L, et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir Med. 2021;9(1): 107–116.
  6. Smadja DM, Mentzer SJ, Fontenay M, et al. COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis. 2021;24(4):755–788.
  7. Potus F, Mai V, Lebret M, et al. Novel insights on the pulmonary vascular consequences of COVID-19. Am J Physiol Lung Cell Mol Physiol. 2020;319(2): L277–L288.
  8. Suh YJ, Hong H, Ohana M, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology. 2021;298(2):E70–E80.
  9. Fu Z, Zhuang X, He Y, et al. The diagnostic value of D-dimer with simplified Geneva score (SGS) pre-test in the diagnosis of pulmonary embolism (PE). J Cardiothorac Surg. 2020;15(1):176.
  10. Xiong W, Zhao Y, Xu M, et al. The relationship between tumor markers and pulmonary embolism in lung cancer. Oncotarget. 2017;8(25):41412–41421.
Creative Commons Attribution License

©2022 Gasparoto, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.